{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:11:27Z","timestamp":1779469887375,"version":"3.53.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05142-w","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:58:42Z","timestamp":1779469122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug development for newborn brain injury"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-7565","authenticated-orcid":false,"given":"Emin","family":"Maltepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"5142_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","volume":"71","author":"GEP Box","year":"1976","unstructured":"Box, G. E. P. Science and Statistics. J. Am. Stat. Assoc. 71, 791\u2013799 (1976).","journal-title":"J. Am. Stat. Assoc."},{"key":"5142_CR2","doi-asserted-by":"publisher","first-page":"152129","DOI":"10.1016\/j.semperi.2025.152129","volume":"49","author":"KQ Zhou","year":"2025","unstructured":"Zhou, K. Q. et al. The advantages and limitations of animal models for understanding acute neonatal brain injury. Semin. Perinatol. 49, 152129 (2025).","journal-title":"Semin. Perinatol."},{"key":"5142_CR3","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1177\/0271678X18797328","volume":"38","author":"RC Koehler","year":"2018","unstructured":"Koehler, R. C., Yang, Z.-J., Lee, J. K. & Martin, L. J. Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy. J. Cereb. Blood Flow. Metab. 38, 2092\u20132111 (2018).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"5142_CR4","doi-asserted-by":"publisher","unstructured":"Barks, J. D. E. et al. Comparing Neuroprotective Drug Efficacy in Rodent Neonatal Brain Injury Models. 2025.09.17.676833 Preprint at https:\/\/doi.org\/10.1101\/2025.09.17.676833 (2025).","DOI":"10.1101\/2025.09.17.676833"},{"key":"5142_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamapediatrics.2013.4208","volume":"168","author":"MM Laughon","year":"2014","unstructured":"Laughon, M. M. et al. Drug labeling and exposure in neonates. JAMA Pediatr. 168, 130 (2014).","journal-title":"JAMA Pediatr."},{"key":"5142_CR6","doi-asserted-by":"publisher","unstructured":"Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. 13311 National Academies Press, Washington, D.C. https:\/\/doi.org\/10.17226\/13311 (2012).","DOI":"10.17226\/13311"},{"key":"5142_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1021\/acschemneuro.7b00040","volume":"8","author":"BH Yokley","year":"2017","unstructured":"Yokley, B. H., Hartman, M. & Slusher, B. S. Role of academic drug discovery in the quest for new CNS therapeutics. ACS Chem. Neurosci. 8, 429\u2013431 (2017).","journal-title":"ACS Chem. Neurosci."},{"key":"5142_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.drudis.2012.07.009","volume":"18","author":"J Blatt","year":"2013","unstructured":"Blatt, J. & Corey, S. J. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov. Today 18, 4\u201310 (2013).","journal-title":"Drug Discov. Today"},{"key":"5142_CR9","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1177\/09622802231184636","volume":"32","author":"R Kelter","year":"2023","unstructured":"Kelter, R. Reducing the false discovery rate of preclinical animal research with Bayesian statistical decision criteria. Stat. Methods Med. Res. 32, 1880\u20131901 (2023).","journal-title":"Stat. Methods Med. Res."},{"key":"5142_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","volume":"22","author":"SJ Ruberg","year":"2023","unstructured":"Ruberg, S. J. et al. Application of Bayesian approaches in drug development: starting a virtuous cycle. Nat. Rev. Drug Discov. 22, 235\u2013250 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"5142_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40290-018-0243-9","volume":"32","author":"KS Valeur","year":"2018","unstructured":"Valeur, K. S., Holst, H. & Allegaert, K. Excipients in neonatal medicinal products: never prescribed, commonly administered. Pharm. Med. 32, 251\u2013258 (2018).","journal-title":"Pharm. Med."},{"key":"5142_CR12","doi-asserted-by":"publisher","unstructured":"Pang, R. et al. Postnatal Azithromycin is neuroprotective and anti-inflammatory in a piglet model of hypoxic-ischemic Encephalopathy. Stroke https:\/\/doi.org\/10.1161\/STROKEAHA.125.054318 (2026).","DOI":"10.1161\/STROKEAHA.125.054318"},{"key":"5142_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36653-9","volume":"13","author":"H Sabir","year":"2023","unstructured":"Sabir, H. et al. Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia\u2013ischemia in newborn rats: a multi-drug randomized controlled screening trial. Sci. Rep. 13, 9467 (2023).","journal-title":"Sci. Rep."},{"key":"5142_CR14","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1161\/STROKEAHA.123.043040","volume":"54","author":"JK Mike","year":"2023","unstructured":"Mike, J. K. et al. Perinatal Azithromycin provides limited neuroprotection in an ovine model of neonatal hypoxic-ischemic Encephalopathy. Stroke 54, 2864\u20132874 (2023).","journal-title":"Stroke"},{"key":"5142_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.earlhumdev.2017.09.007","volume":"114","author":"K Allegaert","year":"2017","unstructured":"Allegaert, K. Better medicines for neonates: Improving medicine development, testing, and prescribing. Early Hum. Dev. 114, 22\u201325 (2017).","journal-title":"Early Hum. Dev."},{"key":"5142_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/17460441.2023.2284824","volume":"19","author":"M Everts","year":"2024","unstructured":"Everts, M. & Drew, M. Successfully navigating the valley of death: the importance of accelerators to support academic drug discovery and development. Expert Opin. Drug Discov. 19, 253\u2013258 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"5142_CR17","doi-asserted-by":"publisher","unstructured":"Mike, J. K. et al. Hypoxanthine-early biomarker of outcomes in an ovine model of neonatal hypoxic ischemic encephalopathy. Pediatr. Res. https:\/\/doi.org\/10.1038\/s41390-026-04856-1 (2026).","DOI":"10.1038\/s41390-026-04856-1"},{"key":"5142_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1377\/hlthaff.2018.05330","volume":"38","author":"TJ Hwang","year":"2019","unstructured":"Hwang, T. J., Bourgeois, F. T., Franklin, J. M. & Kesselheim, A. S. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Aff. 38, 313\u2013319 (2019).","journal-title":"Health Aff."},{"key":"5142_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03097-x","volume":"19","author":"C Mease","year":"2024","unstructured":"Mease, C. et al. Analysis of the first ten years of FDA\u2019s rare pediatric disease priority review voucher program: designations, diseases, and drug development. Orphanet J. Rare Dis. 19, 86 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"5142_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/pr.2016.119","volume":"80","author":"MA Turner","year":"2016","unstructured":"Turner, M. A., McCune, S., Bax, R., Portman, R. J. & Hudson, L. D. The International Neonatal Consortium: collaborating to advance regulatory science for neonates. Pediatr. Res. 80, 462\u2013464 (2016).","journal-title":"Pediatr. Res."},{"key":"5142_CR21","doi-asserted-by":"publisher","first-page":"e2014682","DOI":"10.1001\/jamanetworkopen.2020.14682","volume":"3","author":"G Gresham","year":"2020","unstructured":"Gresham, G., Meinert, J. L., Gresham, A. G. & Meinert, C. L. Assessment of trends in the design, accrual, and completion of trials registered in ClinicalTrials.gov by Sponsor Type, 2000-2019. JAMA Netw. Open 3, e2014682 (2020).","journal-title":"JAMA Netw. Open"},{"key":"5142_CR22","doi-asserted-by":"publisher","first-page":"e2524440","DOI":"10.1001\/jamanetworkopen.2025.24440","volume":"8","author":"B Speich","year":"2025","unstructured":"Speich, B. et al. Nonregistration, discontinuation, and nonpublication of randomized trials: a systematic review. JAMA Netw. Open 8, e2524440 (2025).","journal-title":"JAMA Netw. Open"},{"key":"5142_CR23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMsr1907644","volume":"381","author":"DA Zarin","year":"2019","unstructured":"Zarin, D. A., Fain, K. M., Dobbins, H. D., Tse, T. & Williams, R. J. 10-year update on study results submitted to ClinicalTrials.gov. N. Engl. J. Med. 381, 1966\u20131974 (2019).","journal-title":"N. Engl. J. Med."},{"key":"5142_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2119660","volume":"387","author":"YW Wu","year":"2022","unstructured":"Wu, Y. W. et al. Trial of Erythropoietin for Hypoxic\u2013Ischemic Encephalopathy in newborns. N. Engl. J. Med. 387, 148\u2013159 (2022).","journal-title":"N. Engl. J. Med."},{"key":"5142_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(15)00347-6","volume":"15","author":"D Azzopardi","year":"2016","unstructured":"Azzopardi, D. et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 15, 145\u2013153 (2016).","journal-title":"Lancet Neurol."},{"key":"5142_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00134-018-5293-7","volume":"44","author":"A Lundh","year":"2018","unstructured":"Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B. & Bero, L. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 44, 1603\u20131612 (2018).","journal-title":"Intensive Care Med"},{"key":"5142_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamainternmed.2020.1670","volume":"180","author":"M Gaudino","year":"2020","unstructured":"Gaudino, M. et al. Characteristics of contemporary randomized clinical trials and their association with the trial funding source in invasive cardiovascular interventions. JAMA Intern. Med. 180, 993 (2020).","journal-title":"JAMA Intern. Med."},{"key":"5142_CR28","doi-asserted-by":"crossref","unstructured":"Laterre, P.-F. & Fran\u00e7ois, B. Strengths and limitations of industry vs. academic randomized controlled trials. Clin. Microbiol. Infect. 21, 906\u2013909 (2015).","DOI":"10.1016\/j.cmi.2015.07.004"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05142-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05142-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:58:43Z","timestamp":1779469123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05142-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":28,"alternative-id":["5142"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05142-w","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Scientific Advisory Board, Vessel Sciences, Inc., consultant, Third Pole, Inc., Omniox, Inc., Advisor, Amnion Life, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}